Axsome Therapeutics (Axsome Therapeutics) Gross Margin % : 89.69% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Axsome Therapeutics's Gross Profit for the three months ended in Dec. 2023 was $64.2 Mil. Axsome Therapeutics's Revenue for the three months ended in Dec. 2023 was $71.5 Mil. Therefore, Axsome Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was 89.69%.

The historical rank and industry rank for Axsome Therapeutics's Gross Margin % or its related term are showing as below:

AXSM' s Gross Margin % Range Over the Past 10 Years
Min: 89.61 Med: 89.99 Max: 90.37
Current: 90.37

During the past 11 years, the highest Gross Margin % of Axsome Therapeutics was 90.37%. The lowest was 89.61%. And the median was 89.99%.

AXSM's Gross Margin % is ranked better than
86.12% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs AXSM: 90.37

Axsome Therapeutics had a gross margin of 89.69% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Axsome Therapeutics was 0.00% per year.

Axsome Therapeutics Gross Margin % Historical Data

The historical data trend for Axsome Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Gross Margin % Chart

Axsome Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

89.61

90.37

Axsome Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															90.60	92.01	90.15	88.70	89.69

Competitive Comparison of Axsome Therapeutics's Gross Margin %

For the Biotechnology subindustry, Axsome Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Gross Margin % falls into.

Axsome Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Axsome Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	244.5	/	270.6
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(270.6 - 26.065)	/	270.6
	=	90.37 %

Axsome Therapeutics's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	64.2	/	71.53
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(71.53 - 7.378)	/	71.53
	=	89.69 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Axsome Therapeutics (NAS:AXSM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Axsome Therapeutics had a gross margin of 89.69% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Axsome Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics (Axsome Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

19X:Germany 19X:Germany

Address

22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Executives

Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman	director	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock	officer: General Counsel	22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs	director
Nick Pizzie	officer: Chief Financial Officer	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad	director	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson	officer: Chief Operating Officer	200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek	officer: Chief Commercial Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski	officer: Chief Financial Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye	officer: Chief Medical Officer	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance	officer: Vice President, Finance	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc	10 percent owner	630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111